Williams M, et al. - Researchers investigated cost effectiveness of group B streptococci (GBS) screening using the 2010 guideline (screening at 35 0/7–37 6/7 weeks of gestation) vs the 2019 guideline (screening at 36 0/7–37 6/7 weeks of gestation with re-screening of women with GBS-negative results 5 weeks later). A decision-analysis model was created to compare the outcome of GBS early-onset disease in a hypothetical cohort of 3,614,049 women at 35 0/7 weeks of gestation or greater (the number of live births in 2017 excluding births based on population frequency from 23 to 34 weeks of gestation, women with GBS bacteriuria during the current pregnancy, and those with a history of a previous neonate with GBS disease). Both healthcare and societal perspective were considered and all costs were expressed in 2017 US dollars. Neonatal quality-adjusted life years (QALYs) gained formed the basis for effectiveness. They performed estimation of an incremental cost-effectiveness ratio with a willingness to pay threshold set at $100,000/QALY. The literature was assessed to derive all model inputs. Model assumptions were investigated via one-way probability and cost sensitivity analysis. Outcomes support the cost effectiveness of the 2019 approach, with an incremental cost-effectiveness ratio of $43,205 per neonatal QALY gained.